Moderna/$MRNA
1D1W1MYTD1Y5YMAX
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
- Ticker
- $MRNA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4,700
- Headquarters
- Cambridge, United States
- Website
- www.modernatx.com
Moderna Metrics
BasicAdvanced
$58B
-
-$8.01
0.90
-
Price and volume
Market cap
$58B
Beta
0.9
52-week high
$176.66
52-week low
$22.28
Average daily volume
18M
Financial strength
Current ratio
2.295
Quick ratio
2.068
Long term debt to equity
18.267
Total debt to equity
18.267
Interest coverage (TTM)
-55.36%
Profitability
EBITDA (TTM)
-2,195
Gross margin (TTM)
-66.02%
Net profit margin (TTM)
-141.43%
Operating margin (TTM)
-109.34%
Effective tax rate (TTM)
-2.07%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-13.26%
Return on equity (TTM)
-39.00%
Valuation
Price to revenue (TTM)
25.632
Price to book
8.56
Price to tangible book (TTM)
8.77
Price to free cash flow (TTM)
-45.907
Free cash flow yield (TTM)
-2.18%
Free cash flow per share (TTM)
-3.161
Growth
Revenue change (TTM)
-27.62%
Earnings per share change (TTM)
6.47%
3-year revenue growth (CAGR)
-40.64%
3-year earnings per share growth (CAGR)
37.86%
What the Analysts think about Moderna
Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Moderna Financial Performance
Revenues and expenses
Moderna Earnings Performance
Company profitability
Moderna News
AllArticlesVideos
Moderna Is Betting Big on Its Cancer Vaccine. This Is What Wall Street Wants to See.
Barrons50 minutes ago
Heard on the Street: Moderna's mRNA cancer vaccine marks a major leap in personalized oncology. But the financial math is sobering.
WSJ1 day ago
How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink
WSJ3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.